Ketoprofen - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for ketoprofen and what is the scope of freedom to operate?
Ketoprofen
is the generic ingredient in six branded drugs marketed by Actavis Labs Fl Inc, Alkermes Gainesville, Mylan, Wyeth Pharms Inc, Misemer, Rising, Teva, Wyeth Ayerst, Novartis, Bayer, Perrigo, and Wyeth Cons, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-seven drug master file entries for ketoprofen. Five suppliers are listed for this compound.
Summary for ketoprofen
| US Patents: | 0 |
| Tradenames: | 6 |
| Applicants: | 12 |
| NDAs: | 15 |
| Drug Master File Entries: | 27 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 166 |
| Clinical Trials: | 98 |
| Patent Applications: | 6,849 |
| Drug Prices: | Drug price trends for ketoprofen |
| Drug Sales Revenues: | Drug sales revenues for ketoprofen |
| What excipients (inactive ingredients) are in ketoprofen? | ketoprofen excipients list |
| DailyMed Link: | ketoprofen at DailyMed |
Recent Clinical Trials for ketoprofen
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Osteology Foundation | Phase 4 |
| University of Iowa | Phase 4 |
| Gustavo Avila-Ortiz DDS, MS, PhD | Phase 4 |
Pharmacology for ketoprofen
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Medical Subject Heading (MeSH) Categories for ketoprofen
Anatomical Therapeutic Chemical (ATC) Classes for ketoprofen
US Patents and Regulatory Information for ketoprofen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Pharms Inc | ORUVAIL | ketoprofen | CAPSULE, EXTENDED RELEASE;ORAL | 019816-001 | Sep 24, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms Inc | ORUVAIL | ketoprofen | CAPSULE, EXTENDED RELEASE;ORAL | 019816-002 | Feb 8, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan | KETOPROFEN | ketoprofen | CAPSULE, EXTENDED RELEASE;ORAL | 075679-002 | Feb 20, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms Inc | ORUVAIL | ketoprofen | CAPSULE, EXTENDED RELEASE;ORAL | 019816-003 | Feb 8, 1995 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actavis Labs Fl Inc | KETOPROFEN | ketoprofen | CAPSULE, EXTENDED RELEASE;ORAL | 075270-003 | Mar 24, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva | KETOPROFEN | ketoprofen | CAPSULE;ORAL | 073516-001 | Dec 22, 1992 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Wyeth Ayerst | ORUDIS | ketoprofen | CAPSULE;ORAL | 018754-002 | Jan 9, 1986 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ketoprofen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | ORUDIS | ketoprofen | CAPSULE;ORAL | 018754-001 | Jul 31, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Ayerst | ORUDIS | ketoprofen | CAPSULE;ORAL | 018754-003 | Jan 9, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Wyeth Ayerst | ORUDIS | ketoprofen | CAPSULE;ORAL | 018754-002 | Jan 9, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
